^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ER underexpression

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    Entrez ID:
    2099
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2years
    Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF-7/SC Breast Cancer Cells. (PubMed, Int J Mol Sci)
    Collectively, decreased ER-α expression was restored by pentadecanoic acid treatment, resulting in reversal of tamoxifen resistance. Overall, pentadecanoic acid exhibits the potential to enhance the efficacy of endocrine therapy in the treatment of ER-α-under-expressing breast cancer cells.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • mTOR (Mechanistic target of rapamycin kinase)
    |
    ER underexpression
    |
    tamoxifen
    4years
    [VIRTUAL] Potential value of FOXA1 expression as genomic predictor of response to docetaxel and carboplatin neoadjuvant (NA) chemotherapy in patients with triple negative breast cancer (TNBC) (SABCS 2020)
    Within our cohort, FOXA1 expression is a better predictor of response to NA chemotherapy than AR. FOXA1 is overexpressed in TNBC tumors who do not achieve pCR with neoadjuvant TCb chemotherapy, correlating with non-basal tumor subtypes. This suggests that measuring FOXA1 expression levels in patients with TNBC could be useful to predict response to TCb regimen enabling physicians to select more effective alternative NA schemes in this population.
    Clinical • BRCA Biomarker
    |
    ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • FOXA1 (Forkhead Box A1) • GATA3 (GATA binding protein 3)
    |
    ER positive • AR expression • BRCA1 expression • ER expression • ER underexpression
    |
    carboplatin • docetaxel